Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hinge Health (HNGE) Cash & Equivalents (2023 - 2025)

Hinge Health's Cash & Equivalents history spans 3 years, with the latest figure at $208.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 30.85% year-over-year to $208.0 million; the TTM value through Dec 2025 reached $208.0 million, down 30.85%, while the annual FY2025 figure was $208.0 million, 30.85% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $208.0 million at Hinge Health, down from $214.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $300.8 million in Q4 2024 and bottomed at $208.0 million in Q4 2025.
  • The 3-year median for Cash & Equivalents is $236.6 million (2024), against an average of $242.7 million.
  • The largest annual shift saw Cash & Equivalents grew 28.02% in 2024 before it tumbled 30.85% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $235.0 million in 2023, then rose by 28.02% to $300.8 million in 2024, then crashed by 30.85% to $208.0 million in 2025.
  • Per Business Quant, the three most recent readings for HNGE's Cash & Equivalents are $208.0 million (Q4 2025), $214.0 million (Q3 2025), and $237.2 million (Q2 2025).